AUXL News Alert Auxilium Pharmaceuticals (AUXL) 34.40 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Auxilium Pharmaceuticals (AUXL) 34.40 $AUXL

Endo/BioDelivery File Regulatory Application for Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:45PM CST
Endo International along with its partner BioDelivery Sciences International, Inc. announced the submission of a new drug application for buprenorphine HCl buccal film.
BDSI: 12.65 (+0.66), ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15)

Auxilium Pharmaceuticals Shares Up 69.2% Since SmarTrend's Buy Recommendation (AUXL)
Comtex SmarTrend(R) - Wed Dec 24, 9:35AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 4 months, Auxilium Pharmaceuticals has returned 69.20% as of today's recent price of $34.17.
AUXL: 34.40 (+0.18)

3 Biotech Stocks I Don't Want for Christmas
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 24, 7:50AM CST
With 2014 drawing to a close, biotech investors are probably wondering which stocks to stuff in their stockings for next year. While there are plenty of promising biotech stocks to choose from, we should also take note of three high-risk,...
ENDP: 72.10 (+0.34), INO: 9.11 (-0.09), ZGNX: 1.20 (+0.04), PFE: 31.42 (-0.03), AUXL: 34.40 (+0.18), VVUS: 2.99 (-0.02), TEVA: 57.09 (+0.33), ARNA: 3.57 (-0.01)

Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:10PM CST
Auxilium Pharmaceuticals (AUXL) and partner Sobi's Xiapex is a step closer to EU approval with the CHMP giving a favorable opinion for the treatment of adult men suffering from Peyronie's disease.
ENDP: 72.10 (+0.34), CBST: 100.29 (-0.09), AUXL: 34.40 (+0.18), BIOD: 1.36 (-0.04)

Sobi awarded CHMP's positive opinion for Xiapex for the treatment of Peyronie's disease
M2 - Tue Dec 23, 5:37AM CST
Healthcare company Swedish Orphan Biovitrum AB (Sobi) and partner Auxilium Pharmaceuticals on Monday jointly announced the receipt of positive opinion for Xiapex for treating adult men with Peyronie's disease, a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.
AUXL: 34.40 (+0.18)

Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease
PR Newswire - Mon Dec 22, 6:00AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
AUXL: 34.40 (+0.18)

Uptrend Call Working As Auxilium Pharmaceuticals Stock Rises 63.1% (AUXL)
Comtex SmarTrend(R) - Wed Dec 17, 9:06AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 3 months, Auxilium Pharmaceuticals has returned 63.06% as of today's recent price of $32.93.
AUXL: 34.40 (+0.18)

4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 16, 10:26AM CST
Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, licensing agreements and strong performances.
MDVN: 99.23 (+1.23), OREX: 5.98 (+0.01), ENDP: 72.10 (+0.34), BMRN: 88.18 (+0.89), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15), MNKD: 5.68 (+0.18), CELG: 109.60 (+3.48)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Endo International's SEC form S-4 declared effective
M2 - Fri Dec 12, 7:01AM CST
Healthcare company Endo International (NasdaqGS:ENDP) (TSX:ENL.TO) said on Thursday that its registration statement on Form S-4 has been declared effective by the US Securities and Exchange Commission (SEC) in connection with its acquisition of Auxilium Pharmaceuticals.
ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18)

Auxilium sets special shareholders meeting
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 6:19AM CST

ENDP: 72.10 (+0.34), AUXL: 34.40 (+0.18)

Auxilium Announces Date for Special Meeting of Stockholders
PR Newswire - Thu Dec 11, 4:05PM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that it has scheduled a special meeting of its stockholders for 8:30 a.m. ET on Tuesday, January 27, 2015 to approve matters relating to the previously announced proposed merger with Endo International plc.
AUXL: 34.40 (+0.18)

Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC
PR Newswire Europe - Thu Dec 11, 4:00PM CST
Endo International plc today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the company's Registration Statement on Form S-4. The Form S-4 registers with the SEC Endo's ordinary shares to be issued in connection with the pending acquisition of Auxilium Pharmaceuticals.
ENDP: 72.10 (+0.34), ENL.TO: 83.00 (+0.91), AUXL: 34.40 (+0.18)

Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 114.11 (+0.64), ENDP: 72.10 (+0.34), BDX: 139.90 (+1.44), MDT: 74.08 (+0.31), COV: 103.35 (+0.57), ITMN: 73.89 (-0.02), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), CBST: 100.29 (-0.09), CFN: 59.18 (+0.04), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), IDIX: 24.50 (+0.05), SYK: 96.00 (-0.61), NVS: 93.91 (+0.66)

Shares of AUXL Up 69.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 09, 4:45PM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 3 months, Auxilium Pharmaceuticals has returned 69.00% as of today's recent price of $34.13.
AUXL: 34.40 (+0.18)

Critical Alerts For General Electric, Auxilium Pharmaceuticals, Canadian Solar, JP Morgan Chase and VoxelJet Released By InvestorsObserver
PR Newswire - Thu Dec 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for GE, AUXL, CSIQ, JPM and VJET.
GE: 25.83 (-0.05), JPM: 62.48 (unch), VJET: 7.29 (-0.15), AUXL: 34.40 (+0.18), CSIQ: 22.82 (+0.21)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 47

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
PayPal Adds a Risk Hand to Its Board at a Crucial Turn

Updated Category News Views 91

A Boardroom Hire With Some Actual Weight PayPal did not go hunting for another decorative résumé. Brian J. Lee, set to join the board on November 30, 2026, spent decades inside Goldman Sachs, including a stint as chief risk officer from 2019 through January 2025. For a payments company trying to sharpen its financial-services identity, that is a serious piece of...

Continue Reading
Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 61

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 62

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 133

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 113

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 77

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading

Top 5 Most Recently Viewed Articles

Sarepta Therapeutics Faces Class Action Lawsuit: Key Facts

Updated Category News Views 222

Understanding the Recent Class Action Against Sarepta Therapeutics The law firm of Kessler Topaz Meltzer & Check, LLP has announced an important development for investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT). A securities class action lawsuit has been filed in the Southern District of New York, which impacts those who purchased or otherwise acquired Sarepta's...

Continue Reading
Honoring Dr. Marvin Boomer Jr. and Advocating for Justice

Updated Category News Views 459

A Community's Tribute to Dr. Marvin Boomer Jr. Today we unite not just in sorrow but in a fierce dedication to remember Dr. Marvin Boomer Jr. His life, marked by brilliance and inspiration, serves as a beacon for many. As we reflect on his contributions, we recognize the larger struggles that affect our community. The Impact of Dr. Boomer's Legacy Dr. Marvin Boomer Jr....

Continue Reading
Key Economic Events and Insights from Kashkari's Speech

Updated Category News Views 154

Anticipating Economic Insights from Kashkari's Address As financial markets gear up for another significant day, numerous crucial economic events are set to occur. Traders are especially keen on the insights that FOMC Member Neel Kashkari may share regarding the Federal Reserve's stance on monetary policy. His speech is expected to potentially guide market reactions and...

Continue Reading
Discover Compelling Dividend Stocks for Investors

Updated Category News Views 126

Exploring Attractive Dividend Stocks The stock market has recently reached several new all-time highs, influenced by a variety of economic factors. While this upward trend has benefited many stocks, it has also limited the number of valuable bargains for investors. However, some companies still stand out as exceptional investment opportunities. Currently, three notable...

Continue Reading
New Housing Initiatives in Canada to Combat Housing Shortage

Updated Category News Views 264

Boosting Housing Availability Across Canada The governments are coming together to tackle the pressing issue of affordable housing in Canada. Their concerted efforts have culminated in a substantial funding package aimed at enhancing the housing landscape. Recently, over $44 million has been dedicated towards constructing more than 280 new homes, further expanding the...

Continue Reading